ICCG High Dose Study

Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes.

Disease site: Breast cancer

Treatment Modality: Chemotherapy

Status: Closed

Trial details

The ICCG High Dose Study is a randomised trial evaluating the role of high dose chemotherapy in patients with primary breast cancer. The control arm of the study was based on a conventional 5- fluorouracil–epirubicin-cyclophosphamide (-HDT) regimen and the 'high dose therapy regimen' was designed to consist of three cycles of FEC chemotherapy followed by the high dose cyclophosphamide - thiotepa - carboplatin i.e. CTCb regimen (+HDT). To be eligible, patients had to be free of overt metastatic disease, be less than or equal to 60 years of age with 4 or more histollogically involved lymph nodes.

Recruitment to this study closed on 28/09/02 (281 patients) and active follow up continues.

This is an International Collaborative Cancer Group (ICCG) trial (C/10/92).

Further information

Further information, including contact details for this trial may be found on the ICCG homepage.

Publications and presentations

Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C, Bengala C, Tres A, Welch R, Lawton P, Rubens R, Woods E, Haviland J, Vigushin D, Kanfer E, Bliss JM. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann. Oncol. 2005;16(5):726-34

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story